Bicalutamid-Mepha
Bicalutamid-Mepha Uses, Dosage, Side Effects, Food Interaction and all others data.
Bicalutamid-Mepha is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen.
When Bicalutamid-Mepha is combined with luteinizing hormone releasing hormone (LHRH) analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. However, in clinical trials with Bicalutamid-Mepha as a single agent for prostate cancer, rises in serum testosterone and estradiol have been noted.
In a subset of patients who have been treated with Bicalutamid-Mepha and an LHRH agonist, and who discontinue Bicalutamid-Mepha therapy due to progressive advanced prostate cancer, a reduction in Prostate Specific Antigen (PSA) and/or clinical improvement (antiandrogen withdrawal phenomenon) may be observed.
Bicalutamid-Mepha is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamid-Mepha is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamid-Mepha blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
| Trade Name | Bicalutamid-Mepha |
| Availability | Prescription only |
| Generic | Bicalutamide |
| Bicalutamide Other Names | Bicalutamida, Bicalutamide, Bicalutamidum |
| Related Drugs | estradiol, Premarin, Xtandi, Casodex, Zytiga, Lynparza |
| Type | |
| Formula | C18H14F4N2O4S |
| Weight | Average: 430.373 Monoisotopic: 430.061040456 |
| Protein binding | 96% |
| Groups | Approved |
| Therapeutic Class | Hormonal Chemotherapy |
| Manufacturer | |
| Available Country | Switzerland |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Bicalutamid-Mepha 50 mg daily is used for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.
Bicalutamid-Mepha 150 mg daily is not approved for use alone or with other treatments
Bicalutamid-Mepha is also used to associated treatment for these conditions: Stage D2 Prostatic carcinoma
How Bicalutamid-Mepha works
Bicalutamid-Mepha competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
Dosage
Bicalutamid-Mepha dosage
The recommended dose for Bicalutamid-Mepha therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamid-Mepha be taken at the same time each day. Treatment with Bicalutamid-Mepha should be started at the same time as treatment with an LHRH analog.
Side Effects
Anaemia; angioedema, urticaria; decreased appetite, DM, wt gain, dehydration, gout; decreased libido, depression, anxiety, hypertonia, confusion, neuropathy, nervousness, dizziness, somnolence; hot flush; abdominal pain, constipation, nausea, dyspepsia, flatulence, anorexia, rectal haemorrhage, dry mouth, melaena; hepatotoxicity, jaundice, hypertransaminasaemia; alopecia, hirsutism, dry skin, pruritus/rash, photosensitivity; haematuria, dysuria, urinary retention, impaired urination, urinary frequency; gynaecomastia, breast tenderness, erectile dysfunction; asthenia, oedema, chest pain, neck pain, fever, sepsis, chills, neoplasm; cough, pharyngitis, bronchitis, pneumonia, rhinitis.
Precaution
Patient with decreased bone density, history of or risk factors for QT prolongation, diabetes, Moderate to severe hepatic and severe renal impairment (CrCl <30 mL/min).
Interaction
May induce torsade de pointes or QT prolongation if co-administered with class IA (e.g. quinidine) or class III (e.g. amiodarone) antiarrhythmic agents, methadone, antipsychotics, moxifloxacin. Enhanced anticoagulant effect of warfarin. Increased adverse effects when used with drugs that may inhibit oxidation (e.g. cimetidine, ketoconazole). May increase serum levels of ciclosporin and Ca channel blockers.
Food Interaction
- Take at the same time every day.
- Take with or without food. Food does not significantly affect absorption.
Bicalutamid-Mepha Drug Interaction
Unknown: aspirin, aspirin, aspirin, aspirin, rosuvastatin, rosuvastatin, omega-3 polyunsaturated fatty acids, omega-3 polyunsaturated fatty acids, tamsulosin, tamsulosin, leuprolide, leuprolide, acetaminophen, acetaminophen, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol
Bicalutamid-Mepha Disease Interaction
Elimination Route
Bicalutamid-Mepha is well-absorbed following oral administration, although the absolute bioavailability is unknown.
Half Life
5.9 days
Clearance
- Apparent oral cl=0.32 L/h [Normal Males]
Pregnancy & Breastfeeding use
Pregnancy category X. Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.
Nursing Mothers: Bicalutamid-Mepha is not indicated for use in women.
Contraindication
Females, children, Pregnancy and lactation. Concomitant use of terfenadine, astemizole or cisapride.
Special Warning
Renal Impairment: No dosage adjustment is necessary for patients with renal impairment.
Hepatic Impairment: No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary.
Pediatric Use: The safety and effectiveness of Bicalutamid-Mepha in pediatric patients have not been established.
Geriatric Use: In two studies in patients given 50 or 150 mg daily, no significant relationship between age and steady-state levels of total bicalutamide or the active R-enantiomer has been shown.
Women: Bicalutamid-Mepha has not been studied in women.
Acute Overdose
Long-term clinical trials have been conducted with dosages up to 200 mg of Bicalutamid-Mepha daily and these dosages have been well tolerated. A single dose of Bicalutamid-Mepha that results in symptoms of an overdose considered to be life threatening has not been established. There is no specific antidote; treatment of an overdose should be symptomatic.
In the management of an overdose with Bicalutamid-Mepha, vomiting may be induced if the patient is alert. It should be remembered that, in this patient population, multiple drugs may have been taken. Dialysis is not likely to be helpful since Bicalutamid-Mepha is highly protein bound and is extensively metabolized. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.
Storage Condition
Store at controlled room temperature, 20° to 25° C.
Innovators Monograph
You find simplified version here Bicalutamid-Mepha
Bicalutamid-Mepha contains Bicalutamide see full prescribing information from innovator Bicalutamid-Mepha Monograph, Bicalutamid-Mepha MSDS, Bicalutamid-Mepha FDA label
FAQ
What is Bicalutamid-Mepha used for?
Bicalutamid-Mepha is an antiandrogen medication that is primarily used to treat prostate cancer. It is typically used together with a gonadotropin-releasing hormone analogue or surgical removal of the testicles to treat advanced prostate cancer.
How safe is Bicalutamid-Mepha?
Bicalutamid-Mepha is a new antiandrogen that offers the convenience of once-daily administration, demonstrated activity in prostate cancer, and an excellent safety profile.
How does Bicalutamid-Mepha work?
Bicalutamid-Mepha works by blocking the effects of testosterone (a male hormone), which helps stop the growth and spread of cancer cells.
What are the common side effects of Bicalutamid-Mepha?
Common side effects of Bicalutamid-Mepha are include:
- Bloating or swelling of the face, arms, hands, lower legs, or feet
- blood in the urine
- blurred vision
- body aches or pain
- chills
- congestion
- cough
- cough producing mucus
- difficult or labored breathing
- dizziness
- dryness or soreness of the throat
- fever
- headache
- hoarseness
- lower back or side pain
- nervousness
- painful or difficult urination
- pounding in the ears
- rapid weight gain
- runny nose
- slow or fast heartbeat
Is Bicalutamid-Mepha safe during pregnancy?
This Bicalutamid-Mepha must not be given to a pregnant woman or a woman who intends to become pregnant.
Is Bicalutamid-Mepha safe during breastfeeding?
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Can I drink alcohol with Bicalutamid-Mepha?
Drinking alcohol while taking Bicalutamid-Mepha may produce excessive facial flushing. Avoid drinking alcohol if this becomes bothersome.
Can I drive after taking Bicalutamid-Mepha?
Bicalutamid-Mepha may have an effect on male fertility which could be reversible. Bicalutamid-Mepha is unlikely to affect your ability to drive or to operate machinery. However, some people may occasionally feel drowsy when taking Bicalutamid-Mepha.
When should be taken of Bicalutamid-Mepha?
It is best to take this medicine at the same time each day, in the morning or in the evening. This medicine should be started at the same time as treatment with a luteinizing hormone-releasing hormone analog.
How many time can I take Bicalutamid-Mepha daily?
The usual dose is one tablet daily.
How long does it take Bicalutamid-Mepha to start working?
In some cases (e.g. spinal cord metastasis), Bicalutamid-Mepha will be started approximately 5-7 days before you receive the LHRH agonist. This is done to block the "flare" or surge of testosterone that occurs after LHRH agonist is given.
How long does Bicalutamid-Mepha stay in my system?
Bicalutamid-Mepha takes approximately 30 days for most of the Bicalutamid-Mepha to be removed from your body. If you have severe liver impairment it will take longer.
How long can I take Bicalutamid-Mepha ?
You take it for a few days before starting the luteinising hormone blocker, and stay on it for about 4 to 6 weeks.
Can I just stop taking Bicalutamid-Mepha?
Do not stop taking these medicines without checking with your doctor first.
Who should not take Bicalutamid-Mepha?
You should not use this medicine if you are allergic to Bicalutamid-Mepha. Tell your doctor if you have or have ever had liver disease. you should know that Bicalutamid-Mepha is only for use in men. If taken by pregnant women, Bicalutamid-Mepha can cause abnormalities in the fetus. Women who are or may become pregnant should not take Bicalutamid-Mepha.
What happens if I miss a dose?
Skip the missed dose and use your next dose at the regular time. Do not use two doses at one time. Call your doctor for instructions if you miss an appointment for your LHRH injection.
What happen If I suddenly stop taking Bicalutamid-Mepha?
When you stop taking Bicalutamid-Mepha it takes approximately 30 days for most of the Bicalutamid-Mepha to be removed from your body. If you have severe liver impairment it will take longer.
Can I overdose on bransd?
If you take too much Bicalutamid-Mepha, call your healthcare provider or Poison Control Center or go to the nearest hospital emergency room right away.
Can Bicalutamid-Mepha cause heart problems?
The Naranjo scale strongly suggests that Bicalutamid-Mepha was the cause of heart failure.
Does Bicalutamid-Mepha increase testosterone?
Bicalutamid-Mepha increases both testosterone and estradiol levels, and the estradiol levels approximate the low-normal levels of a premenopausal woman.
Will Bicalutamid-Mepha affect my fertility?
Bicalutamid-Mepha may be affected by Bicalutamid-Mepha.
Can Bicalutamid-Mepha affect my kidneys?
Androgens and anabolic steroids, including testosterone, have trophic and anabolic effects in the kidneys. Androgen deprivation therapy, including with GnRH agonists and Bicalutamid-Mepha monotherapy, may increase the risk of kidney failure in men.
Can Bicalutamid-Mepha affects my liver?
Bicalutamid-Mepha monotherapy has been found to cause unfavorable liver changes in around 3% of men, with such changes necessitating discontinuation in about 0.3 to 1% of men. Very rarely, Bicalutamid-Mepha has been associated with liver damage, lung disease, and sensitivity to light.
